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BACKGROUND
Chronic obstructive pulmonary disease (COPD) puts a high burden
on patients and governmental health-care budgets.1,2 General
practitioners (GPs) have a pivotal role in the treatment of COPD
patients in primary care. However, the strategies of treatment may
differ considerably between individual GPs, resulting in large intra-
individual differences in health-care utilisation and quality of life
of their patients.3,4 Recently, the Spanish AUDIPOC study showed
great variability in hospital treatment patterns and patients’
outcomes.5 Moreover, the European COPD audit indicated marked
differences in resources available across different hospitals in
Europe.6 In Spain though, it is estimated that at least 61% of COPD
patients are only treated in primary care,7 with an average of 6.6
visits per year. The estimated prevalence of COPD in the Balearic
Islands is 12.8%.8 Regarding health-care costs for respiratory
patients, several cost drivers, mostly related to patient character-
istics, have been identiﬁed in previous studies including
associated comorbidities (e.g., heart disease), forced expiratory
volume in 1 s (FEV1), the physical component of quality of life, 6-
min walking distance, increased dyspnoea, number of medical
visits and hospitalisations.9–11 Although one study identiﬁed an
effect of the individual physician on health-care costs,12 treatment
strategies were never incorporated as a predicting variable for
costs or outcomes. Besides inter-physician differences in treat-
ments, country-speciﬁc regulations and difference in the extent of
adherence to clinical guidelines may affect the cost-effectiveness
of treating COPD patients in primary care settings.13 It was shown
that adherence to COPD treatment guidelines is suboptimal.14
Moreover, non-adherence to guidelines was associated with
higher total health-care costs.15 In particular, in times of increasing
health-care costs and scarcer resources, there is a need to identify
the cost-effectiveness of different treatment strategies for COPD
patients across various primary care settings. The UNLOCK project
of the International Primary Care Respiratory Group (IPCRG) offers
a promising possibility.16
AIMS
The primary aim of this study is to assess what makes one COPD
treatment strategy more cost-effective than others, by taking into
account factors related to patients, the physician, and speciﬁc
follow up and treatment approaches. A secondary objective is to
assess whether real-world cost-effectiveness of treatments is
comparable between Spain and other countries that have
comparable data sets available.
METHODS
Study design
This is a cost-effectiveness analysis that is performed with a real-world
database on respiratory patients.
Setting
This study comprises two phases, with the ﬁrst phase including all primary
care centres in the Balearic Islands, Spain. In a second phase of the study,
primary care centres from other parts of the world will be included.
Data source
All the data will be extracted from the MAJOrca Real-world Investigation in
COPD and Asthma database (MAJORICA). The MAJORICA database
contains combined data from the primary care system (e-SIAP), the
hospital claims system (FIC), and the pharmacy database (RELE) in the
Balearics, Spain. Together, these databases cover all health-care utilisation
of the permanent inhabitants of the Balearics (±1.1 million subjects). In the
Balearics, there are about 400 different GPs, and most of the COPD patients
are treated by one of these GPs. The MAJORICA database contains data
from all patients aged ⩾ 18 years with a primary care diagnosis of asthma
and/or COPD in 2012, regardless of health insurance. All demographics,
clinical data, diagnostic tests, as well as resource use, pharmacy dispense
data, work absence and patient-reported outcomes from almost 70,000
respiratory patients are available for the period 2011–2014. A speciﬁcation
of the database is provided in Table 1. The database characteristics were
reported according to the checklists of the IPCRG16 and the Respiratory
Effectiveness Group (http://www.effectivenessevaluation.org). The unique
island setting of the Balearics allows us to provide an almost complete
picture of the real-world health-care use of COPD patients.
Inclusion criteria
All patients (⩾18 years) with a clinical diagnosis of COPD (ICD-9 codes: 491,
492, 496 and/or primary codes R79, R95) in 2012, available in the
MAJORICA database, were included. In addition, patients needed to be a
permanent resident of the Balearic Islands and to be alive in 2014.
Health-care resource utilisation
Health-care resource use in 2013 and 2014 will be calculated for all the
COPD patients identiﬁed in 2012. Health-care resource use that will be
included in the study refers to the following: GP visits, primary care nurses
visits, emergency department (ED) visits, specialist visits, specialist nurse
visits, hospitalisations, medication and diagnostic tests (that is, spirometry,
CT-scans, X-rays, bronchoscopy). To estimate indirect costs, data on work
absence will be extracted. These data will be extracted from the e-SIAP
system, as work absence in Spain is registered by GPs.
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Calculation of health-care costs and indirect costs
Total costs will be calculated by multiplying each unit of resource use and
lost workdays with standard cost-per-unit prices, which are obtained from
the Health Care Administration Ofﬁce of the Balearics.17
Predictors for cost-effectiveness
Predictors for cost-effective treatment will be assessed, including variables
related to patient, physician or treatment. Predictors related to patients
may include age, gender, body mass index, smoking status, exacerbations
(physician diagnosis and/or prescription of prednisone), COPD severity by
spirometry, short-acting β2-agonist use, health-related quality of life and
comorbidity. Examples of predictors related to the physician are age,
gender and setting, number of patients per practice and number of COPD
patients per practice. Predictors related to treatment may include
prescription of medication and adherence based on reﬁll of medication,
inﬂuenza vaccination in the past year, requests for diagnostic tests,
referrals to hospital or specialists and the use of patient-reported outcomes
(PROs).
Comparisons
Speciﬁcations of the comparisons that could potentially be made,
depending on the exact data available, are listed in Table 2.
Table 1. Speciﬁcation of the MAJORICA database
Variable Speciﬁcation
Type of database
Electronic Medical Record Yes
Claims Yes
Country/countries of data origin Balearics,
Spain
Number of patients 68,578
Patients with asthma diagnosis (ICD-9: 493) 45,800
Patients with COPD diagnosis (ICD-9: 491, 492, 496) 27,871
Patients with asthma and COPD diagnosis (ICD-9:
493 and (491. 492, 496))
5,093
Data collection (period) 2011–2014
Unique identiﬁer/anonymisation Yes
Ethical approval Yes
Coding system diseases
ICD-9, ICD-10, read ICD-9
Patient demographics
Gender Yes
Age Yes
BMI Yes
Physician demographics
Gender Yes
Age Yes
Setting (urban/rural) Yes
Drugs
Coding ATC-7
Prescribed, dispensed, both Dispensed
Drugs available All R03
Dose/dosing Yes
Device No
OTC medications No
Inhaler technique No
Vaccinations
Inﬂuenza, Pneumococcal Yes
Outcomes
Exacerbations
Steroids Yes
Antibiotics Yes
SABA Yes
Exacerbations (ICD-9 code) Yes
Health resource utilisation
Primary care consultations Yes
Secondary care consultations Yes
Consultations coded by disease Yes
Consultations coded by routine/emergency Yes
Hospitalisations Yes
Hospitalisations coded by disease Yes
Hospitalisation duration Yes
Emergency room Yes
ICU Yes
ICU coded by disease Yes
ICU duration Yes
Rehabilitation No
Physiotherapy No
Patient-reported
mMRC Yes
Asthma (ACQ, ACT) ACT score
COPD (CCQ, CAT) CAT score
Side effects
Pneumonias Yes
Work absence
All cause Yes
Respiratory speciﬁc Yes
Table 1. (Continued )
Variable Speciﬁcation
Covariates
Comorbidities
Diabetes Yes
Cardiovascular diseases
Hypertension Yes
Cardiac insufﬁciency
Atrial ﬁbrillation
Cor pulmonale
Allergic rhinitis Yes
Cerebrovascular disease Yes
Osteoporosis Yes
Sleep apnoea Yes
Nasal polyps No
Depression/anxiety Yes
Reﬂux (GERD) Yes
Chronic kidney disease Yes
Lung Cancer Yes
AIDS/HIV Yes
Cognitive dysfunction No
Risk score
Cardiovascular risk score Yes
Lifestyle
Smoking status Yes
Smoking years Yes
Socioeconomic status
Post code No
Education level No
Employment status Yes
Salary range No
Spirometry
FEV1/FVC, FEV1%pred, reversibility Yes
Laboratory tests
Full blood count, FeNO, IgE and so on No
Imaging
CRX Performed Y/N
HRCT Performed Y/N
Abbreviations: ACT, asthma control test; ATC, anatomical therapeutic
chemical; BMI, body mass index; CAT, COPD Assessment Test; CRX, chest
X-ray; FEV, forced expiratory volume; FVC, forced vital capacity; GERD,
gastroesophageal reﬂux disease; HRCT, high-resolution computed tomo-
graphy; ICD, International Classiﬁcation of Diseases; ICU, intensive care
unit; mMRC, modiﬁed Medical Research Council; N, no; OTC, over the
counter; SABA, short-acting beta agonists; Y, yes.
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Data analysis
The total patients’ sample will be split into two groups, depending on the
treatment variables that will be compared (Table 2). For example, to assess
the impact of using PROs, all patients who were treated by a GP who uses
PROs will be selected as the treatment group. An equal group of control
patients, not treated by a GP who uses PROs, will be selected using a
matching procedure. The matching procedure (based on propensity
scores) will use patient characteristics (age, gender, smoking status) and
disease severity (FEV1, exacerbations, quality of life, comorbidities).
For both groups, the average total costs per patient (as well as minimum,
maximum and standard deviation) will be calculated on the basis of the
direct health-care costs, as listed above (hospitalisations, medication, ED
visits), and indirect costs. The cost difference between the two groups will
result in a ΔC variable to obtain an estimate of the incremental costs. The
differences in effect size (ΔE) will be expressed as the difference in health
effects between the two groups that are compared. The health effects
depend on what variables will be consistently available in the database.
Exacerbations avoided will be used, as well as changes in COPD-speciﬁc
changes in the quality of life, as deﬁned by the COPD Assessment Test (CAT)
or modiﬁed Medical Research Council (mMRC) questionnaire.
Subsequently, the incremental cost-effectiveness ratio (ICER) can be
calculated as follows: (Costsgroup1−Costsgroup2)− (Effectsgroup1−Effectsgroup2)=
ΔC/ΔE, which provides the incremental costs per exacerbation avoided or
incremental costs per CAT point gained. The ICER will be calculated using both
the health-care payer’s and the societal perspective. The societal perspective
includes work productivity costs. Sensitivity analyses will be performed
using the minimal and maximal costs (scenario analyses), as well as a
bootstrap procedure (as patient-level data will be available). Bootstrapping
relies on random sampling with replacement, and it will allow estimating
accuracy (such as 95% conﬁdence intervals) to sample estimates.
External validity using UNLOCK
Once the predictors have been identiﬁed, we will invite members of the
UNLOCK project in other countries (e.g., The Netherlands, Sweden and
others) to participate to test the external validity and inter-country
variation of these predictors.
To assure consistency of the analytic process and consequent results,
data will be compared with other data sets from different IPCRG countries,
including the same variables and applying the same methods.
Ethical approval
Ethical approval was granted by the local primary care research committee.
DISCUSSION
Current clinical treatment guidelines are mainly based on evidence
from large clinical trials with a selective study population, which
does not seem to reﬂect the majority of patients treated in real-
world primary care.18,19 Therefore, there is an urgent need to assess
the validity of treatment recommendations when applied in real-
world treatment. Results from this study are expected to provide
useful insights in the cost-effectiveness of the broad range of
strategies and factors related to the primary care treatment of
COPD. The use of a real-world database that covers the complete
Balearic population is considered a major strength, as a represen-
tative population is assessed in which the risk of pre-selection bias
is limited. A second strength is that results will be compared with
other international settings, thereby increasing generalisability.
Here, the UNLOCK project of IPCRG offers a useful possibility.16
However, given the retrospective observational design, some
limitations should be acknowledged. First, by the use of real-
world data, missing data are common. In particular, registration of
data regarding the use of spirometry, smoking status and patient-
reported outcomes is expected to be limited. Pulmonary rehabilita-
tion and physiotherapy data are not included in the effectiveness
analysis because of the difﬁculty in collecting such data and
because of the limited availability of these services. In addition,
miscoding or incomplete and invalid data collection may have
occurred because of the real-word setting. Another limitation lies in
the observational design, which usually increases the risk for bias.
Although the database itself covers the complete population, the
individual analyses are prone to selection bias. To minimise this risk
of bias, a matching procedure will be used, but unobserved bias
may still occur. Despite these limitations, the need for more real-
world evidence and comparative effectiveness research is increas-
ing, thereby strengthening the overall relevance of this study.20
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